Skip to main content
Clinical Trials/NCT04495166
NCT04495166
Completed
Not Applicable

Smartphone-Assisted Brief Behavioral Intervention for Pregnant Women With Depression

University of Sao Paulo1 site in 1 country81 target enrollmentAugust 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Perinatal Depression
Sponsor
University of Sao Paulo
Enrollment
81
Locations
1
Primary Endpoint
Change in Maternal Prenatal Depression at Baseline, Midpoint, and Posttreatment (8 Weeks)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Investigators developed Motherly 1.0, a smartphone app designed to treat and promote maternal mental health. A 2-arm parallel-randomized controlled clinical trial (RCT) will be conducted to test the efficacy of Motherly in conjunction with brief cognitive-behavioral therapy. 70 pregnant women between 16-40 years old will be recruited. Since all interventions will be conducted online, participants will be recruited from any Brazilian state or municipality. Participants will be randomly assigned to either receive intervention via app consisting of behavioral activation and psychoeducation to promote changes in sleep, nutrition, and physical activity habits, as well as to engage in prenatal care, breastfeeding, and social support, and to stimulate child development, in addition to brief cognitive-behavioral therapy (CBT) (n=35); or to a comparison group receiving an psychoeducational app (active control) with psychoeducational content about gestation, maternal health and mental health, and child development in addition to brief CBT (n=35). Duration of treatment will be eight weeks, during which participants in both groups will be assessed at the beginning (baseline; T0), weeks 3-4 (midpoint; T1), and week 8 (endpoint; T2) in order to evaluate treatment effects. A follow-up postnatal assessment will also be conducted when the child is three months of age (T3).

Registry
clinicaltrials.gov
Start Date
August 3, 2020
End Date
April 27, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Guilherme Vanoni Polanczyk, MD PhD

Professor

University of Sao Paulo

Eligibility Criteria

Inclusion Criteria

  • women aged between 16-40 years;
  • having a score of \>7 on the Edinburgh Postnatal Depression Scale (EPDS);
  • gestational age between 17-26 weeks;
  • being literate;
  • owning a functional smartphone with Android for personal use.

Exclusion Criteria

  • pregnancies classified as being at risk, fetal malformation, or congenital disease;
  • visual, auditory or intellectual disabilities, or chronic diseases associated with fetal development alterations;
  • severe and/or chronic mental disorder (e.g., schizophrenia, bipolar disorder, etc).

Outcomes

Primary Outcomes

Change in Maternal Prenatal Depression at Baseline, Midpoint, and Posttreatment (8 Weeks)

Time Frame: Baseline (T0), Weeks 3-4 (Midpoint, T1), Week 8 (Posttreatment, T2).

Participants were assessed with the Edinburgh Postnatal Depression Scale (EPDS) at baseline, at 4 weeks, and at 8 weeks (posttreatment). (EPDS max-min scores=0-30, higher scores=worse outcome).

Secondary Outcomes

  • Change in Maternal Prenatal Anxiety From Baseline to Posttreatment (8 Weeks)(Baseline (T0), Weeks 3-4 (Midpoint, T1), Week 8 (Posttreatment, T2).)
  • Change in Maternal Prenatal Quality of Life From Baseline to Posttreatment (8 Weeks)(Baseline (T0), Weeks 3-4 (Midpoint, T1), Week 8 (Posttreatment, T2).)
  • Change in Maternal Prenatal Psychological Well-Being From Baseline to Posttreatment (8 Weeks).(Baseline (T0), Week 8 (Posttreatment, T2).)
  • Change in Maternal Prenatal Perceived Stress From Baseline to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Depression Severity From Baseline to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Perceived Stress From Baseline to Posttreatment (8 Weeks).(Baseline (T0), Weeks 3-4 (Midpoint, T1), Week 8 (Posttreatment, T2).)
  • Change in Maternal Prenatal Sleep Quality From Baseline to Posttreatment (8 Weeks).(Baseline (T0), Weeks 3-4 (Midpoint, T1), Week 8 (Posttreatment, T2).)
  • Infant Social/Emotional Problems at 2 Months of Age.(When the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Physical Activity Levels From Baseline to Posttreatment (8 Weeks).(Baseline (T0), Week 8 (Posttreatment, T2).)
  • Change in Maternal Prenatal Depression Severity From Baseline to Posttreatment (8 Weeks).(Weeks 3-4 (Midpoint, T1), Week 8 (Posttreatment, T2).)
  • Infant Developmental Milestones at 2 Months of Age.(When the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Depression From Baseline to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Anxiety From Baseline to to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Quality of Life From Baseline to to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Psychological Well-Being From Baseline to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)
  • Change in Maternal Prenatal Sleep Quality From Baseline to Follow-up.(Baseline (T0), when the infant is two months of age (Follow-up, T3).)

Study Sites (1)

Loading locations...

Similar Trials